hexamethonium has been researched along with Obesity in 4 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the pathophysiological role of leptin in obesity-related hypertension, we examined cardiovascular phenotypes of transgenic skinny mice whose elevated plasma leptin concentrations are comparable to those seen in obese subjects." | 7.70 | Pathophysiological role of leptin in obesity-related hypertension. ( Aizawa-Abe, M; Ebihara, K; Hayashi, T; Hosoda, K; Inoue, G; Iwai, H; Masuzaki, H; Matsuoka, N; Nakao, K; Ogawa, Y; Satoh, N; Yoshimasa, Y, 2000) |
| "To explore the pathophysiological role of leptin in obesity-related hypertension, we examined cardiovascular phenotypes of transgenic skinny mice whose elevated plasma leptin concentrations are comparable to those seen in obese subjects." | 3.70 | Pathophysiological role of leptin in obesity-related hypertension. ( Aizawa-Abe, M; Ebihara, K; Hayashi, T; Hosoda, K; Inoue, G; Iwai, H; Masuzaki, H; Matsuoka, N; Nakao, K; Ogawa, Y; Satoh, N; Yoshimasa, Y, 2000) |
| "Obesity is one of the major risk factors for cardiovascular disease and is often associated with increased oxidative stress and sympathoexcitation." | 1.35 | Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in obesity-induced hypertension. ( Ando, K; Fujita, M; Fujita, T; Kawarazaki, H; Matsui, H; Nagae, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagae, A | 1 |
| Fujita, M | 1 |
| Kawarazaki, H | 1 |
| Matsui, H | 1 |
| Ando, K | 1 |
| Fujita, T | 1 |
| Van Vliet, BN | 1 |
| Hall, JE | 1 |
| Mizelle, HL | 1 |
| Montani, JP | 1 |
| Smith, MJ | 1 |
| Carlson, SH | 1 |
| Shelton, J | 1 |
| White, CR | 1 |
| Wyss, JM | 1 |
| Aizawa-Abe, M | 1 |
| Ogawa, Y | 1 |
| Masuzaki, H | 1 |
| Ebihara, K | 1 |
| Satoh, N | 1 |
| Iwai, H | 1 |
| Matsuoka, N | 1 |
| Hayashi, T | 1 |
| Hosoda, K | 1 |
| Inoue, G | 1 |
| Yoshimasa, Y | 1 |
| Nakao, K | 1 |
4 other studies available for hexamethonium and Obesity
| Article | Year |
|---|---|
Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in obesity-induced hypertension.
Topics: Acetophenones; Animals; Blood Pressure; Brain; Cyclic N-Oxides; Heart Rate; Hexamethonium; Hypertens | 2009 |
Reduced parasympathetic control of heart rate in obese dogs.
Topics: Animals; Atropine; Baroreflex; Cardiovascular System; Dogs; Heart Rate; Hemodynamics; Hexamethonium; | 1995 |
Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Glucose; B | 2000 |
Pathophysiological role of leptin in obesity-related hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; alpha-MSH; Animals; Blood Pressure; Body | 2000 |